The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study measures changes in vascular compliance with teriparatide 1 hour, 3 months, and 6 months after initiating teriparatide. Osteoprotegerin and RANKL levels [ Time Frame: baseline, 3, and 6 months ]
Secondary Outcome Measures :
CRP levels [ Time Frame: Baseline and at 6 months of therapy ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
40 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide
Patients with diabetes mellitus
patients with a history of organ transplantation
Patients currently of previously on glucocorticoid therapy within the past year
Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
History of radiation therapy
Patients pregnant or nursing
History of bone metastasis or skeletal malignancies